Acronym:
ORAL MUCOSITIS
ACTRN/NCT /ethics:
Scientific title:
Summary of trial and patient characteristics
| Cancer Type | Head and Neck | ||
|---|---|---|---|
| Trial Type | Treatment | ||
| Phase | Phase II, Phase I | Tumour Stream | Head and Neck |
| Age Range | 18 years and older | Cancer Stage | Clinical Trials - Cancer Stage |
| Sex | Both | Anticipated Start Date | |
| Molecular Target | Anticipated End Date | ||
| Cancer Type | Head and Neck |
|---|---|
| Trial Type | Treatment |
| Phase | Phase II, Phase I |
| Age Range | 18 years and older |
| Sex | Both |
| Molecular Target | |
| Tumour Stream | Head and Neck |
| Cancer Stage | Clinical Trials - Cancer Stage |
| Anticipated Start Date | |
| Anticipated End Date |
Trial Summary
A phase 1b/2, multicanter, randomised study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of ST-617 for the attenuation of oral mucositis in patients receiving chemoradiation for head and neck cancer.
Lay Summary
Sponsor / Cooperative group
Participating Hospitals
| Hospital | Clinical Trial Coordinator | Phone | Principal Investigator | Recruitment Status | |
|---|---|---|---|---|---|
| Flinders Medical Centre | Alex Scott-Hoy | alex.scott-hoy@sa.gov.au | 08 8204 4830 | Shawgi Sukumaran | Not Yet Recruiting |